Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Numinus Wellness reports revenue decline but bets on growth through psychedelic approvals

Numinus Wellness reported a 15.4% decrease in revenue to $5.03 million in the second quarter of 2024, along with a lower gross profit and rising operating expenses. The company is strategically positioning itself for the anticipated approval of psychedelic therapies, particularly MDMA for PTSD, and is focusing on diversification through research, education, and clinical services. Despite short-term financial challenges, Numinus aims for positive EBITDA through cost savings and a strengthened cash position. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Numinus Wellness has already paid €0.50 in dividends. The last payout was in October 2022.

Financials

In the last quarter, Numinus Wellness had revenue of €998.36K and net profit of -€186.36K

(EUR)	May 2026	YoY
Revenue	998.36K	13.65%
Gross profit	510.7K	8.48%
Net profit	-186.36K	59.14%
EBITDA	-99.13K	69.66%

Fundamentals

Metric	Value
Market capitalization	€5.2M
Number of shares	320.55M
52-week high/low	€0.0496 - €0.0018
Dividends	No
Beta	2.77
P/E ratio	-0.75
PEG ratio	-0.01
P/B ratio	20.34
P/S ratio	3.84

Company profile

Numinus Wellness Inc. provides solutions to develop and deliver psychedelic-assisted psychotherapy and transform the mental health landscape. The company operates in two divisions, Salvation Botanicals and Numinus Health. The Salvation Botanicals division offers laboratory services, such as cultivation, analytical testing, product research and development, and ancillary services in the area of psychedelics; and full suite testing and custom testing of cannabis. The Numinus Health division provides supportive therapies and technologies to heal, connect, and grow with a focus on treating mental health and substance abuse; and services for psychotherapy, counselling, neurofeedback, physiotherapy, and other therapies. This division also offers training, facilities, and other operational resources to practitioners. The company is headquartered in Vancouver, Canada.